Unicycive Therapeutics (UNCY) Free Cash Flow (2020 - 2026)

Unicycive Therapeutics (UNCY) has 7 years of Free Cash Flow data on file, last reported at -$6.2 million in Q1 2026.

• Quarterly Free Cash Flow rose 29.94% year-over-year to -$6.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$28.7 million (up 7.82% YoY) and the FY2025 annual result came in at -$31.3 million, down 9.4% from the prior year.
• Free Cash Flow grew to -$6.2 million in Q1 2026, from -$8.0 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of -$3.0 million in Q1 2022 to a low of -$9.3 million in Q3 2024.
• A 5-year average of -$5.9 million and a median of -$6.1 million in 2022 frame the typical range for Free Cash Flow.
• Annual changes were most pronounced in 2022 — Free Cash Flow slumped 1304.15% — and 2025, when it surged 35.71%.
• Tracing UNCY's Free Cash Flow over 5 years: stood at -$6.1 million in 2022, then grew by 27.04% to -$4.4 million in 2023, then tumbled by 48.01% to -$6.6 million in 2024, then decreased by 22.25% to -$8.0 million in 2025, then increased by 22.2% to -$6.2 million in 2026.
• The last three Free Cash Flow figures came in at -$6.2 million (Q1 2026), -$8.0 million (Q4 2025), and -$6.0 million (Q3 2025), per Business Quant data.